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Background: It is important to prevent complications of implanted pulse generators (IPG) depletion by replacing
the IPG in time.
Methods: We reviewed the charts of all patients with deep brain stimulation treated movement disorders who
were seen at our institution over a period of 6 months. Among these, we retained for analyses those who had
undergone IPG replacement within the previous 3 years.
Results: A total of 55 IPG replacements (from 38 patients) were reviewed. Electrodes were implanted in the
subthalamic nucleus in all Parkinson’s disease patients, in the ventral intermedius nucleus of the thalamus in all
essential tremor patients and in the globus pallidus interna in all dystonia patients. Replacements were preceded by
a voltage increase due to worsened symptoms in 27.3% (15/55); 25.5% (14/55) had full IPG depletion or had too
low IPG reserve to allow for any voltage adjustment; and 21.7% (12/55) did not get a needed voltage increase
either for safety reasons (eg: concern for increase in falls with higher voltages) or because the surgery date for IPG
replacement was close. Only 25.5% (14/55) remained clinically well-controlled prior to IPG replacement, all of whom
had IPG longevity estimates available. Clinical deterioration was noted prior to IPG replacement in 100% of patients
without available longevity estimates versus 61% of patients with available longevity estimates (p < 0.001).
Conclusion: Despite best efforts, clinical deterioration prior to IPG replacement can be seen frequently. Routine
estimation of IPG life, along with symptom assessment at every follow-up visit may prevent it.
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Deep brain stimulation (DBS) has been approved by the
United States Food and Drug Administration (FDA) for
the treatment of Parkinson’s disease (PD), essential
tremor (ET) and dystonia, and is undergoing trials for
approval in psychiatric disorders such as depression and
obsessive compulsive disorders.
DBS acts through delivering an electrical current in a
specific target area of the brain, the target being different
according to the disease being treated. This current can be
modulated through modification of voltage, frequency and
duration of each electrical pulse delivered. The delivered* Correspondence: raja.mehanna@uth.tmc.edu
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unless otherwise stated.energy creates an electrical field of variable size and shape
according to the parameters used for stimulation [1]. The
current is generated by an implantable pulse generator
(IPG), a small pacemaker-like unit that is implanted under
the skin, usually in the chest or less frequently in the ab-
domen. The current is then delivered through an exten-
sion wire and implanted electrode to the target located
deep in the brain. Once the IPG is depleted, it has to be
replaced so current can continue to be generated and de-
livered to the brain.
Because IPG depletion can result in worsening of
neurological symptoms [2,3], and sometimes lead to
medical emergencies [4,5], it is important to prevent it
by replacing the IPG in time. This can be done by rou-
tinely estimating IPG life and assessing symptoms at
every follow-up visit. For the Soletra model, estimateral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients characteristics
Average Range
Age 67.8 years 23–90 years
M/F ratio 2/1
Age of battery when replaced 4.3 years 1.2–9 years
Battery voltage when replaced 3.39 V 0-3.74 V
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port. Reported DBS settings are entered into a computer
software which estimates the longevity of the IPG from
the date of implant. A web based application developed
by the University of Florida is also available [6]. However,
the estimation of IPG life is always an approximation be-
cause the actual IPG life depends upon multiple specific
DBS treatment parameters, duration of stimulation, lead
impedance, as well as many other factors that cannot eas-
ily be estimated [7]. While increasing DBS settings corre-
lates inversely with IPG longevity [8], guidelines provided
by medical device companies to help approximate the lon-
gevity of an IPG cannot take into consideration all pos-
sible therapeutic combinations of DBS and are thus far
from accurate, especially because DBS treatment parame-
ters change over time with the evolution of the underlying
disease. There are many more sources of error that may
flaw longevity estimation, including but not limited to
device-to-device variation, decreased supplied voltage with
battery usage, battery chemistry, impedance fluctuation
and battery self-discharge through quiescent current [7].
There is little information in the literature regarding
practices when DBS batteries are about to be depleted of
power. We reviewed all IPG replacements done at our in-
stitution over a period of 42 months to survey our practice
patterns, including DBS programming modifications, when
DBS batteries are nearing end of life.
Methods
We reviewed the charts of all patients with movement dis-
orders who underwent DBS surgery and who were seen
at the Center for Neurological Restoration at Cleveland
Clinic between 06/01/2012 and 12/31/2012. We retained
for analyses those who had undergone IPG replacement
within the previous 3 years. All batteries replaced being of
the Soletra model (Medtronic ® Minneapolis, MN, USA),
we included all replacements that were done for an IPG
voltage of 3.69 or less, or for a drop by 0.3 V or more in
the previous 12 months, or for clinical worsening that im-
proved after IPG replacement, or at the family’s insistence
because the predicted lifespan was reached. We excluded
the IPG replacements that were done for other reasons
(e.g. replacing the non-depleted contralateral IPG to spare
the patient another surgery within a year). The patient’s
age, gender, diagnosis, duration of disease at time of IPG
replacement, IPG model and voltage at the last visit before
IPG replacement were noted. The presence of symptoms
attributed at the time by the treating clinician to IPG de-
pletion and programming changes to address these symp-
toms were also recorded, as well as whether the IPG
longevity estimate was known at the last visit before re-
placement, obtained through the Medtronic helpline. This
was a minimal risk study utilizing existing data through
chart review and not requiring any direct patient evaluationfor the purpose of the study. Data was de-identified, in-
formed consent was waived and the study was submitted to
the Cleveland Clinic Foundation Institutional Review Board
who exempted it from review.Results
A total of 55 IPG replacements, involving 38 patients,
with 25 (66%) males and a mean age of 67.8 years (range
23 to 90 years), were ultimately included in this survey
(Table 1). The diagnoses included PD (44 replacements),
ET (5 replacements), primary generalized dystonia with
DYT 1 mutation (2 replacements), primary segmental
dystonia (1 replacement), secondary generalized dystonia
(2 replacements) and secondary segmental dystonia (1
replacement) (Figure 1). All PD patients had their elec-
trodes implanted in the subthalamic nucleus; ET patients
had their electrodes implanted in the ventral intermedius
nucleus of the thalamus; and all patients with dystonia
had theirs implanted in the globus pallidus interna. On
average, the batteries were 4.3 years old (range 1.2 –
9 years) and had a mean voltage of 3.39 (range 0 – 3.74 V)
when they were replaced (Table 1). When assessing IPG
longevity by diagnosis, the mean lifespan was 5.75 years in
ET (range 4–6.75 years, SD 1.09, SEM 0.5), 4.4 years in
PD (range 1.5-9 years, SD 2.02, SEM 0.3) and 1.9 years
in dystonia (range 1.2 to 3 years, SD 0.73, SEM 0.3)
(F = 6.451, p = 0.003) (Figure 2).
In 15 of 55 (27.3%) replacements, patients required a
voltage increase due to worsened symptoms (mean voltage
increase = 0.26 V; SD = 0.1; range: 0.1-0.5 V) (Figure 3).
This increase at least partially improved the symptoms
until the IPG was replaced. Moreover, for these patients,
the side effects noted after IPG replacement often re-
quired voltage re-adjustment back to their pre-power de-
pletion levels. In 14 (25.5%) additional replacements, a
needed voltage adjustment could not be performed be-
cause of either full IPG depletion or too low IPG reserve,
with the concern that such increase would precipitate de-
pletion before replacement. Additionally, 12 (21.7%) re-
placements did not get a needed voltage increase either
for safety reasons such as concern for increase in falls with
higher voltages or because patient declined it as surgery
date was close (Figure 3). Only 14 of 55 (25.5%) replace-
ments were clinically well-controlled prior to IPG power
depletion (Figure 3). Their IPGs were replaced well ahead
Figure 1 Diagnosis distribution. Legend: PD: Parkinson’s disease, ET: essential tremor, DYT 1: generalized dystonia with DYT 1 mutation,
PSD: primary segmental dystonia, SGD: secondary generalized dystonia, SSD: secondary segmental dystonia.
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necessary.
In 33 of 55 (60%) of the replacements, the IPG longev-
ity estimate was available. Twenty of these (61%) had
motor deterioration before IPG replacement, 5 of which
benefited from a voltage increase prior to IPG replace-
ment. 6 replacements were done at the patient’s and fam-
ily insistence based on previous estimates, despite good
IPG reserve and the lack of symptoms of IPG depletion.
In contrast, all the 22 replacements that did not have esti-
mates available had symptoms of depletion before IPG re-
placement. The difference in the proportion of patients
who experienced worsening of symptoms prior to IPG
replacement between the group with estimates available
(61%) versus the group without available estimates (100%)
was statistically significant using a Chi square test (Chi-













Figure 2 IPG longevity per diagnosis in years. Legend: IPG: implantableDiscussion
In our retrospective review of 55 IPG replacements in
38 patients, the most frequent diagnosis was PD (76.3%),
followed by dystonia (13.2%) then ET (10.5%). We have
found that the average longevity of the Soletra IPG was
consistent with previous reports for patients with dys-
tonia at 1.9 years [9-12] and PD at 4.4 years [6,8,13,14].
However, the IPG lasted longer that previous reports in
our patients with ET (5.75 vs 2 to 4 years) [6,8,12,13],
likely because most of our ET patients turn their IPG off
at night precisely to prolong its life. Overall, this was
consistent with previously published data that the under-
lying diagnosis can also affect IPG longevity with the
characteristics of the stimulation target as well as the
disease pathophysiology likely contributing to battery
longevity [6,12,13], with dystonia typically depleting the
IPG faster than PD or ET.PD Dystonia
gnosis
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Figure 3 Programming change prior to surgery.
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curred frequently. Fifteen of 55 (27.3%) replacements
benefited clinically from a voltage increase (mean voltage
increase = 0.26 V; SD = 0.1; range: 0.1-0.5 V). Interest-
ingly, side effects noted after IPG replacement often re-
quired a voltage re-adjustment to their pre-power depletionPatien
Clinically worsening
Check IPG estimator vs 
implantation date (for newer 
models: check the  electronic 
replacement indicator)
Could battery life explain the 
symptoms?
Consider risk and benefits of 
battery replacement.
Figure 4 Suggested algorythm for management of IPG life. Legend: IPGlevels. In 14 of 55 (25.5%) replacements, patients were clin-
ically worse but could not get a needed voltage increase be-
cause of either full IPG depletion or too low IPG reserves.
Finally, 14 of 55 (25.5%) IPGs were replaced well ahead of
full depletion and no programming adjustments were ne-
cessary before or after IPG replacement. All of the lattert with DBS
Clinically stable
Check IPG estimator vs 
implantation date (for newer 
models: check the  electronic 
replacement indicator)
Monitor patient clinically and with 
estimates at successive visits.
Plan timimg of preemptive IPG 
replacement: maximize IPG life 
without risking rebound of 
symptoms.
: implantable pulse generator.
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knowing these longevity estimates prevented clinical de-
terioration prior to IPG replacements in several patients
in our cohort—clinical deterioration was noted in 100% of
IPG replacement without longevity estimates, whereas it
was seen in 61% of IPG replacements with available lon-
gevity estimates (p < 0.001).
Available data regarding the clinical usefulness of lon-
gevity estimate are conflicting. In a prospective study on
72 IPG replacements, Stewart and Eljamel [15] demon-
strated large differences between the actual longevity
and the longevity predicted using a computer-based esti-
mate integrating current DBS parameters. There was no
correlation between the 2, and the actual longevity was
shorter by a year in some instances. However, in a retro-
spective review of 320 charts, Fakhar et al. demonstrated
that an University of Florida web based estimator/smart
phone application (r = .67, p < .001) as well as the Med-
tronic helpline estimate (r = 0.74, p < 0.001) were corre-
lated with the actual IPG life [6].
Our study replicate the results from Fakhar et al., albeit
on a smaller sample and without the use of the University
of Florida estimator. These studies actually complement
each other with an emphasis on the physical and electrical
aspect in Fakhar et al.’s, and on the clinical aspect in ours.
The IPG longevity in ET patients was, however, longer in
our study (5.75 vs 3.54 years). In our study, knowledge of
the estimate was associated with a lower rate of symptom-
atic IPG depletions. However, because only 4 of the 55
IPGs were totally depleted at the time of surgery, we could
not compare the estimated lifetime to the actual lifetime
of the IPGs.
While this study has some limitation inherent to its
small size and retrospective design such as reliance on
recorded data and chart quality, as well as lack of
randomization, we believe it is a useful survey of practice
patterns at our institution and suggests that IPG longevity
estimate is useful in clinical practice. Considering that 6 of
55 (11%) of replacements in our study were done at the
patients or family insistence because the predicted lifetime
was coming to an end, although there were no clinical or
electrical signs of depletion, the question of cost effecti-
veness of relying solely on longevity estimate should be
raised. However, this contrasts with previous reports
where the actual life expectancy was typically shorter than
estimated [15]. It thus seems that both the estimate as well
as the electrical and/or clinical worsening should be taken
into consideration when deciding of the best time to re-
place the IPG, supporting an algorithm previously sug-
gested by Montuno et al. (Figure 4) [7].
Finally, all the patients in this study were found to
have the Soletra model of IPG. This specific model is old
and has been replaced by newer models such as Activa.
The newer models have an elective replacement indicatormessage that is displayed on patient and clinician pro-
graming devices, and suggests that a replacement may be
required within approximately three months. The newer
models probably predict battery failure more accurately,
and the results of our study might not apply to them.
However, clinicians taking care of the non-negligible num-
ber of patients still carrying Soletra, and until these de-
plete and get replaced by a newer model, will find our
results still useful and clinically relevant.
Conclusions
The patients who had optimal symptom control were
those seen well in advance of power depletion, with
enough time to have batteries replaced before their symp-
toms worsened. However, clinical deterioration just prior
to end of IPG life was not uncommon. A significant per-
centage of patients required voltage adjustments prior to
IPG placement to improve their worsening clinical state,
and often required another voltage readjustment after IPG
replacement. Because IPG depletion can lead to worsening
of neurological symptoms and even medical emergencies
on one hand, and overzealous IPG replacement may not
be cost-effective on the other, DBS programming clini-
cians should routinely estimate IPG life and assess symp-
toms at every follow-up visit in order to decide when IPGs
should be replaced.
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